FDA Improves Drug Review Timeframes, Aims For Original PDUFA Standard
This article was originally published in The Tan Sheet
Executive Summary
After an almost two-year hiatus from strict adherence to Prescription Drugs User Fee Act review timeframes, Office of New Drugs Director John Jenkins has told review staff that, once again, they should strive to meet the user fee deadlines